Anti-Prostaglandin D Synthase (lipocalin-type, human) (Clone 10A5)

Prostaglandin D synthase (PGDS) catalyzes the isomerization of PGH2 to produce PGD2. PGD2 induces sleep, regulates nociception, inhibits platelet aggregation, and acts as an allergic mediator. Two distinct types of PGDS have been identified, namely the lipocalin type enzyme (beta-trace) and the hematopoietic enzyme. Lipocalin-type PGDS is localized in the central nervous system, genital organs of various mammals and the human heart. Patients with chronic renal failure and hypertension exhibit elevated amounts of lipocalin-type PGDS in serum and urine. The lipocalin-type PGDS has been identified as beta-trace (~24 kDa), which is a major protein in the human cerebrospinal fluid.Synonyms: beta-Trace Protein, Cerebrin-28, Glutathione-independent PGD Synthase, L-PGDS, Lipocalin-PGDS, PGDS2, Prostaglandin-H2 D-isomerase. Immunogen: Recombinant human L-PGD synthase. Clone Designation: 10A5. Formulation: (Request formulation change), 200 µg of ion-exchange chromatography purified antibody. Storage Buffer: PBS, pH 7.2, when reconstituted in 500 µl deionized water. Host: Rat. Isotype: IgG1kappa. Applications: IHC and WB. UniProt Accession #: P41222. Origin: Animal/Rat.